Press ReleaseView printer-friendly version << Back
Medtronic's OsteoCool™ Procedure Shows Significant, Swift Pain Relief and Sustained Improvement for Cancer Patients
"The rapid pain relief was arguably the most important finding from the study. Also, given the significant improvement in quality of life we saw in such a sick patient population, we're hopeful this meaningful data provides evidence to support moving this therapy up earlier in the cancer treatment paradigm."
Cancer that has metastasized, or moved to surrounding bone, can affect quality of life, producing complications such as pain, fractures, and decreased mobility.1 In addition to these symptoms, bone metastases can cause mood changes such as depression and anxiety.2 Radiation therapy is traditionally considered the gold standard palliative treatment for patients with bone metastases. But 1 in 3 cancer patients are left with inadequate treatment or undermanaged pain control because treatments like opioids, chemotherapy, and radiation therapy did not work for them.3 OsteoCool™ system can be used as an adjunctive treatment in this instance and it does not disrupt other systemic therapies.
"Our Interventional Pain Therapies business is inherently connected to the
According to the study results, patients treated with RFA achieved significant improvements in pain relief (worst and average pain) at all visits. Results showed rapid pain improvement as early as 3 days and sustained out to 6 months. Patients in the study also achieved significant improvements in pain interference and quality of life at all visits. Pain interference measures seven interference items (general activity, mood, walking ability, normal work, relations with other people, sleeping, and enjoyment of life).
The multicenter center study included a total of 218 patients at 16 centers in
The OPuS One primary endpoint was achieved through these results – to demonstrate an improvement from baseline to 3 months post-RFA in worst pain score in the past 24 hours in subjects treated for metastatic lesions in only the thoracic and/or lumbar vertebral body(ies). Eighty-seven percent of patients had tumors involving the thoracolumbar spine and thirteen percent had tumors located in the pelvis and/or sacrum.
About the OsteoCool™ Radiofrequency Ablation System
The OsteoCool™ System is intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body and for ablation of benign bone tumors such as osteoid osteoma. It is also intended for coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. The system is contraindicated for use in the cervical spine. Risks for the system include damage to surrounding tissue through iatrogenic injury as a consequence of electrosurgery, pulmonary embolism, and nerve injury including thermal injury, puncture of the spinal cord or nerve roots potentially resulting in radiculopathy, paresis, and paralysis.
About the J Vasc Interv Radiol (JVIR) Publication
Levy J, Hopkins T, Morris J, et al. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. J Vasc Interv Radiol 2020; 31:1745–1752. https://doi.org/10.1016/j.jvir.2020.07.014
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the
- Goetz, et al. Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study. J Clin Oncol. 2004; 22 (2): 300-306.
- Spiegel D, et al. Pain and depression in patients with cancer. Cancer. 1994;74:2570-2578.
- Anselmetti, et al. Treatment of Extraspinal Painful Bone Metastases with Percutaneous Cementoplasty: A Prospective Study of 50 Patients. Cardiovasc Intervent Radiol. 2008;31:1165-1173.
View original content to download multimedia:http://www.prnewswire.com/news-releases/medtronics-osteocool-procedure-shows-significant-swift-pain-relief-and-sustained-improvement-for-cancer-patients-301192321.html